Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of a Novel Soluble Epoxide Hydrolase Inhibitor as a Strategy for Treating Neuropathic Pain in Patients With SCI

NCT06438471 is registered in ClinicalTrials.gov with EicOsis Human Health Inc. as lead sponsor.

NCT NCT06438471
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06438471 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of a Novel Soluble Epoxide Hydrolase Inhibitor as a Strategy for Treating Neuropathic Pain in Patients With SCI
Lead sponsor
EicOsis Human Health Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
May 1, 2026
Completion date
December 31, 2027
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

degenerative disc disease, neuropathic pain, spinal cord injuries, spinal stenosis, spondylosis